Advertisement


Nasser K. Altorki, MD, on Lung Cancer: Radiotherapy and Immune Checkpoint Blockade in the Neoadjuvant Setting

AACR Virtual Annual Meeting 2020 II

Advertisement

Nasser K. Altorki, MD, of Weill Cornell Medical College, discusses study findings that suggest neoadjuvant low-dose focal stereotactic body radiation plus immune checkpoint blockade (ICB) is safe and causes no surgical delays in early-stage lung cancer, and that major pathologic response rates are likely to be comparable to those with chemotherapy/ICB combinations (Session ED37).



Related Videos

Issues in Oncology
Leukemia

Alfonso Bencomo Álvarez, PhD, on ALL, AML, and CML: Survival for Hispanic Patients Living Near the US/Mexico Border

Alfonso Bencomo Álvarez, PhD, of Texas Tech University Health Sciences Center, discusses his retrospective study of the incidence and survival for patients with hematologic malignancies residing at the United States/Mexico border. The analysis showed that 10-year survival rates for Hispanic patients with ALL, AML, and CML were significantly lower for those who lived in El Paso than for those who lived elsewhere in Texas (Abstract 4343).

Immunotherapy

Ralph R. Weichselbaum, MD, on Radiotherapy and Immunotherapy in Oligometastatic Disease

Ralph R. Weichselbaum, MD, of the University of Chicago Cancer Research Center, explores the question of whether radiotherapy is the principal curative treatment with immunotherapy or activates immunotherapy. He also discussed how to improve the interaction of these treatments, perhaps with vaccination, transfer of genetically engineered T cells, or checkpoint inhibitors (Session ED37).

Issues in Oncology

Adam C. Palmer, PhD, on Immune Checkpoint Inhibitors: Additive to or Synergistic With Other Treatments?

Adam C. Palmer, PhD, of the University of North Carolina at Chapel Hill, discusses combining immune checkpoint inhibitors with other cancer therapies to provide patients with more chances of a response. In principle, similar benefits may result from sequential or biomarker-stratified treatments, which could be valuable in cases where toxicities may prevent full-dose combinations (Abstract 1047).

COVID-19

Robert A. Winn, MD, on the Impact of COVID-19 on Cancer Care Among Racial and Ethnic Minorities

Robert A. Winn, MD, of Virginia Commonwealth University and the Massey Cancer Center, discusses the COVID-19 pandemic and how it is exacerbating disparities in cancer care among racial and ethnic minorities and the medically underserved who are disproportionately affected by the coronavirus (Session VSS06).

Lung Cancer

Ramaswamy Govindan, MD, on Differences Among Male and Female Patients With Lung Cancer

Ramaswamy Govindan, MD, of Washington University School of Medicine, discusses sex differences in lung cancer, including variations in treatment response, and the state of research in the field (Session ED20).

Advertisement

Advertisement




Advertisement